Please login to the form below

Not currently logged in
Email:
Password:

abatacept

This page shows the latest abatacept news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –

Latest news

More from news
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept)  . 245. Athersys/ Healios. Licence. Development and commercialisation

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • BMS’ Brian Daniels to retire BMS’ Brian Daniels to retire

    Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....